SymBiosis and HealthTech Arkansas Form BioAR Trial Accelerator
yahoo.com
news
2022-10-19 13:00:00

Will provide companies in late pre-clinical to early-clinical stages of development access to high-quality trial sites in Arkansas to bring groundbreaking therapies to market faster

Designed to increase Arkansans' access to cutting-edge clinical care and innovative medicines

Application now open for inaugural cohort beginning in April 2023

BENTONVILLE, Ark., October 19, 2022--(BUSINESS WIRE)--SymBiosis Capital Management, LLC ("SymBiosis") and HealthTech Arkansas today announced the formation of BioAR Trial, an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans' access to cutting-edge clinical care and innovative medicines.
